Literature DB >> 10230867

Glucocorticoid-induced secondary osteopenia in female rats: a time course study as compared with ovariectomy-induced osteopenia and response to salmon calcitonin.

T Nitta1, T Fukushima, H Nakamuta, M Koida.   

Abstract

Previously we reported that 8-week treatment with methylprednisolone acetate (MPA: 0.1 mg/kg, s.c., 3 days a week) of male rats caused a novel type of osteopenia whose development was prevented by salmon calcitonin (SCT) in a dose-dependent manner. In this study, to compare the MPA-inducible osteopenia with the ovariectomy (OVX)-inducible one, female rats were used instead of male rats and a time-course study of development was made. MPA treatments for 1, 2, 4 and 8 weeks histologically induced characteristic osteopenic changes in a time-dependent manner that were histomorphometrically detectable in tibiae within 4 weeks as reduced bone mass, accelerated bone resorption, and suppressed bone formation and mineralization. Node-strut analysis revealed that the connectivity of the trabecular structure remained unaffected. Such MPA-induced changes in the trabecular structure, to be defined as thinned-but-uncut, is in a good contrast with OVX-induced unthinned-but-cut structure, although the latter osteopenic changes became detectable 2 weeks earlier. Another previous finding confirmed herein was that MPA-induced osteopenia in female rats was also completely masked by SCT (10 U/kg, s.c., 5 days a week). The results indicate that the MPA-inducible secondary osteopenic model in either sex of rats would be usable for testing anti-osteopenic drugs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10230867     DOI: 10.1254/jjp.79.379

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  6 in total

1.  Activation of Trk neurotrophin receptors by glucocorticoids provides a neuroprotective effect.

Authors:  Freddy Jeanneteau; Michael J Garabedian; Moses V Chao
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-17       Impact factor: 11.205

2.  Thermosensitive drug delivery system of salmon calcitonin: in vitro release, in vivo absorption, bioactivity and therapeutic efficacies.

Authors:  Yu Tang; Jagdish Singh
Journal:  Pharm Res       Date:  2009-12-09       Impact factor: 4.200

Review 3.  Animal models for osteoporosis.

Authors:  R T Turner; A Maran; S Lotinun; T Hefferan; G L Evans; M Zhang; J D Sibonga
Journal:  Rev Endocr Metab Disord       Date:  2001-01       Impact factor: 6.514

Review 4.  The laboratory rat as an animal model for osteoporosis research.

Authors:  Pavlos P Lelovas; Theodoros T Xanthos; Sofia E Thoma; George P Lyritis; Ismene A Dontas
Journal:  Comp Med       Date:  2008-10       Impact factor: 0.982

5.  Anti-osteoporosis effect of 5-bromo-2-(4-chlorobenzoyl)-(Z)-3-(2-cyano-3-hydroxybut-2-enonyl)aminobenzo[b]furan: a novel selective estrogen receptor modulator.

Authors:  Ryo Fukuyama; Akio Shimokawa; Yasushi Kodama; Mitsugu Fujita; Yoshitaka Ohishi; Yuko Ando; Masao Koida; Hiromichi Nakamuta
Journal:  J Pharmacol Sci       Date:  2011-05-21       Impact factor: 3.337

6.  Comparison of the effect of vitamin K(2) and risedronate on trabecular bone in glucocorticoid-treated rats: a bone histomorphometry study.

Authors:  Jun Iwamoto; Hideo Matsumoto; Tsuyoshi Tadeda; Yoshihiro Sato; James K Yeh
Journal:  Yonsei Med J       Date:  2009-04-30       Impact factor: 2.759

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.